TORONTO, May 17, 2012 /CNW/ - Spectral Diagnostics Inc., (TSX:SDI, OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that Dr. Paul Walker, the Company's President and Chief Executive Officer, will present at BioFinance 2012 on Wednesday, May 30, at 9:20 a.m. Eastern Time. The conference will be held at the St. Andrew's Club & Conference Centre in Toronto, Ontario.
Dr. Walker will provide a corporate update, including information about the Company's pivotal sepsis program.
BioFinance is a prominent Canadian investor conference for the life sciences industry. The two-day event brings together key industry players interested in investment opportunities and issues affecting companies in the life sciences sector. Presenting companies span a range of industries including biologics, medical devices, drug delivery, vaccines, and diagnostics.
About Spectral Diagnostics
Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment for severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.
Toraymyxin has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively in more than 80,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, and in November 2010, signed an exclusive distribution agreement for this product in Canada. More than 250,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $1 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol SDI, and on the OTQ QX under the symbol DIAGF. For more information please visit www.spectraldx.com
For further information:
Executive Vice President and CFO
416-626-3233 ext. 2200
Media and Investor Relations
416-815-0700 ext. 225